Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says
May 7, 2014 9:00 AM EDTJefferies analyst Eun K. Yang, Ph.D lowered his price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) to $61.00 (from $80.00) following 'surprisingly' weak Q1 Juxtapid sales.
Yang comments, "While AEGR is confident of meeting its ~5% lowered guidance ($180M-$200M), surprisingly weak 1Q14 Juxtapid... More
Aegerion (AEGR) PT Lowered to $70 at Deutsche Bank Due to Slow Patient Growth
May 7, 2014 8:37 AM EDTDeutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) an reduced its price target to $70.00 (from $115.00). Analyst Robyn Karnauskas expressed caution due to slow patient growth.
"Juxtapid 1Q revenues at $27M were lower than consensus at $33.6M primarily due to lower sales in ex-US.... More
Cowen Downgrades Aegerion Pharmaceuticals (AEGR) to Market Perform
May 7, 2014 7:27 AM EDTCowen downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Outperform to Market Perform with a price target of $36.00 (from $85).
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $44.16 yesterday.
... More